ARTICLE | Company News
Accentia autoimmune news
June 14, 2010 7:00 AM UTC
Accentia filed a proposed plan of reorganization with the U.S. Bankruptcy Court for the Middle District of Florida, Tampa Division, as part of its Chapter 11 proceedings. The company expects to emerge from bankruptcy this summer after which it will announce plans to start Phase III testing for its Revimmune cyclophosphamide to treat multiple sclerosis (MS). Accentia has exclusive, worldwide rights to the ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC (Tampa, Fla) under a 2007 deal. ...